2026.05.14
On May 12, 2026 — Dake Biosciences (Dake), a clinical-stage biotechnology company developing molecular glue degrader drugs, announced that it had signed an agreement with Merck Research Laboratories (China) Co., Ltd. (Merck) to advance the clinical co-development of anti-tumor drugs.
Dr. Lihui Zou, co-founder and CEO of Dake Biosciences, stated: "We are very pleased to reach this collaboration with Merck to jointly advance the clinical development of Dake Biosciences' novel molecular glue degrader anti-tumor drugs. This collaboration fully validates the scientific value and clinical potential of our innovative projects. With Merck's extensive experience and leading capabilities in clinical development and oncology, we look forward to accelerating the development of breakthrough therapies, continuously moving towards the goal of improving patient health and benefiting patients worldwide."
"We are delighted to collaborate with Dake to explore the potential of novel molecular glue degraders in the field of oncology treatment," said Dr. Zhengqing Li, Senior Vice President of Merck and President of the China R&D Center. "Dake Biosciences has demonstrated impressive innovation in the discovery of molecular glues and targeted protein degradation. We look forward to combining our strengths to accelerate the clinical development of innovative candidate drugs, bringing more breakthrough treatment options to patients worldwide."
JunHe was entrusted by Dake Biosciences to review, amend and negotiate the agreement for this project. We earned the trust and recognition of the client with our consistently efficient, rigorous work style and meticulous, dedicated service attitude.
The lead partner for this project was XIONG, Tao and the main handling partner was ZHAO, Hao (Gerry).
